These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24758387)

  • 1. The role of interferon in the new era of hepatitis C treatments.
    Parekh PJ; Shiffman ML
    Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):649-56. PubMed ID: 24758387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C therapy: Looking toward interferon-sparing regimens.
    Au TH; Destache CJ; Vivekanandan R
    J Am Pharm Assoc (2003); 2015; 55(2):e72-84; quiz e85-6. PubMed ID: 25658389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future perspectives: towards interferon-free regimens for HCV.
    Gane E
    Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus: standard-of-care treatment.
    Pawlotsky JM
    Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs in development for chronic hepatitis C: a promising future.
    Pockros PJ
    Expert Opin Biol Ther; 2011 Dec; 11(12):1611-22. PubMed ID: 21995412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-combination strategies for the treatment of chronic hepatitis C.
    Aronsohn A; Jensen D
    Semin Liver Dis; 2014 Feb; 34(1):30-6. PubMed ID: 24782256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hepatitis C virus: 25 years-old, the end?].
    Pol S
    Med Sci (Paris); 2013 Nov; 29(11):998-1003. PubMed ID: 24280503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
    Welsch C; Jesudian A; Zeuzem S; Jacobson I
    Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy.
    Alhamlan FS; Al-Ahdal MN; Khalaf NZ; Abdo AA; Sanai FM; Al-Ashgar HI; Elhefnawi M; Zaid A; Al-Qahtani AA
    J Med Virol; 2014 Feb; 86(2):224-34. PubMed ID: 24166351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now.
    Florian J; Mishra P; Arya V; Harrington P; Connelly S; Reynolds KS; Sinha V
    Clin Pharmacol Ther; 2015 Oct; 98(4):394-402. PubMed ID: 26179495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapeutic approaches for hepatitis C.
    Au JS; Pockros PJ
    Clin Pharmacol Ther; 2014 Jan; 95(1):78-88. PubMed ID: 24126682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C Virus: Current and Evolving Treatments for Genotype 4.
    Asselah T; Bourlière M
    Gastroenterol Clin North Am; 2015 Dec; 44(4):859-70. PubMed ID: 26600224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development.
    Pawlotsky JM
    Semin Liver Dis; 2014 Feb; 34(1):22-9. PubMed ID: 24782255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
    Hara T; Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Kumada H
    J Med Virol; 2013 Oct; 85(10):1746-53. PubMed ID: 23861088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
    Miyasaka A; Kumagai I; Abe K; Suzuki K
    Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficiency of second pegylated interferon and ribavirin combination treatment for the relapsed hepatitis C virus infection in low-income countries.
    Ceylan B; Arslan F; Yardimci C; Fincanci M; Özgüneş N
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):493-4. PubMed ID: 24598385
    [No Abstract]   [Full Text] [Related]  

  • 20. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.